Cargando…
Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations
OBJECTIVE: To evaluate the benefit–risk profile (BRP) of oxycodone/naloxone (OXN) and tapentadol (TAP) in patients with chronic low back pain (cLBP) with a neuropathic component (NC) in routine clinical practice. METHODS: This was a blinded end point analysis of randomly selected 12-week routine/ope...
Autores principales: | Ueberall, Michael A, Mueller-Schwefe, Gerhard H H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115682/ https://www.ncbi.nlm.nih.gov/pubmed/27881925 http://dx.doi.org/10.2147/JPR.S112418 |
Ejemplares similares
-
Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
por: Ueberall, Michael A, et al.
Publicado: (2016) -
Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids
por: Ueberall, Michael A, et al.
Publicado: (2015) -
Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release
por: Bacallao, Jorge, et al.
Publicado: (2016) -
Tapentadol and Oxycodone/Naloxone Prescribing Patterns in Primary Health Care in Catalonia, Spain: A Cross-Sectional Study
por: Viñas-Bastart, Montserrat, et al.
Publicado: (2021) -
Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study
por: Barrachina, Jordi, et al.
Publicado: (2022)